Dr. Ravi Sahu obtained his B.Sc in biology, Physics and chemistry from Allahabad University and M.Sc in biochemistry from Dr. R.M.L. Avadh University in India. He completed Ph.D from Sanjay Gandhi Postgraduate Institute of Medical Sciences at Lucknow, India. He then began his postdoctoral career determining the role of natural compounds in cancer chemoprevention at University of Pittsburgh at Pittsburgh, PA and Texas Tech University Health Sciences Center at Amarillo, TX. His second postdoctoral work at Indiana University was focused on investigating the impact of various pro-oxidative stressors in the pathogenesis of cutaneous immunity and non-melanoma skin cancer. Currently he is an Assistant Professor in the Department of Pharmacology and Toxicology, Boonshoft School of Medicine at Wright State University, Ohio, United States.
Oxidative stressors; Lipid mediators; Cancer chemoprevention and therapeutics; Cell signaling pathways; Genetic and Epigenetics; Gene regulation; Cancer biomarkers; Apoptotic and autophagy pathways; DNA damage and repair pathways.
1. Sahu RP, Aggarwal A, Zaida G, Shah A, Modi K, Kongara S, Aggarwal S, Talwar S, Chu S, Bhatia V and Bhatia E. Etiology of early-onset type 2 diabetes in Indians: islet autoimmunity andmutations in HNF 1 alpha and mitochondrial gene. Journal of Clinical Endocrinology and Metabolism 2007; 92 (7), 2462-2467.
2. Shi Y, Sahu RP, Srivastava SK. Triphala inhibits both in vitro and in vivo xenograft growth of pancreatic tumor cells via inducing apoptosis. BMC Cancer 2008; 8: 294.
3. Zhang R, Humphreys I, Sahu RP, Shi Y, Srivastava SK. In-vitro and in-vivo induction of apoptosis by Capsaicin in pancreatic cancer cells is mediated through ROS generation and mitochondrial death pathway. Apoptosis 2008; 13 (12), 1465-1478.
4. Sahu RP, Srivastava SK. The role of STAT-3 in the induction of apoptosis in pancreatic cancer cells by benzyl isothiocyanate. Journal of National Cancer Institute 2009; 101(3), 176-193.
5. Sahu RP, Batra S, Srivastava SK. Activation of checkpoint kinase 1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. British Journal of Cancer 2009; 100(9), 1425-1433.
6. Sahu RP, Zhang R, Batra S, Shi Y, Srivastava SK. BITC induced activation of ERK causes cell cycle arrest and induces apoptosis via generation of ROS in human pancreatic cancer cells. Carcinogenesis 2009; 30 (10), 1744-1753.
7. Sahu RP, Epperly MW, Srivastava SK. Benzyl isothiocyanate sensitizes human pancreatic cancer cells to radiation therapy. Frontiers in Bioscience (Elite Ed). 2009, 1:568-76.
8. Batra S#, Sahu RP#, Kandala PK, Srivastava SK (2010). Benzyl Isothiocyanate mediated histone deacetylase inhibition leads to turn-off of NF-κB in human pancreatic carcinoma cell lines. (# are equal contributors) Molecular Cancer Therapeutics, 9 (6), 1596-608.
9. Wicker CA#, Sahu RP#, Kulkarni-Datar K*, Srivastava SK, Brown TL. BITC sensitizes pancreatic adenocarcinoma to TRAIL-induced apoptosis. (# are equal contributors) Cancer Growth and Metastasis 2010; 2009 (2), 45-55.
10. Sahu RP, Batra S, Brown TL, Srivastava SK. The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cells. Chemotherapeutics and Pharmacology 2011; 67 (2), 481-487.
11. Boreddy SR, Sahu RP, Srivastava SK. Benzyl Isothiocyanate Suppresses Pancreatic Tumor Angiogenesis and Invasion by inhibiting HIF-1α/VEGF/Rho-GTPases: Pivotal Role of STAT-3. PLOS One 2011; 6 (10): e25799.
12. Lupov IP, Voiles L, Han L, Schwartz A, Dela Rosa M, Oza K, Pelloso D, Sahu RP, Travers JB, Robertson MJ, Chang HC. Acquired STAT4 deficiency as a consequence of cancer chemotherapy. Blood 2011; 118: 6097-106.
13. Sahu RP, Kozman A, Yao Y, DaSilva SC, Rezania S, Martel KC, Warren S, Travers JB, Konger RL. Loss of the Platelet Activating Factor Receptor in mice augments PMA-induced inflammation and cutaneous chemical carcinogenesis. Carcinogenesis 2012; 33:694-701.
14. Sahu RP, DaSilva SC, Rashid B, Martel KC, Rezania S, Jernigan D, Bradish JR, Armstrong AB, Warren S, Konger RL. Mice lacking epidermal PPARγ exhibit a marked augmentation in photocarcinogenesis associated with increased UVB-induced apoptosis, inflammation and barrier dysfunction. International Journal of Cancer 2012; 131: E1055-1066.
15. Sahu RP, Turner MJ, DaSilva SC, Rashid BM, Ocana JA, Perkins SM, Konger RL, Touloukian CE, Kaplan MH, Travers JB. The environmental stressor ultraviolet B radiation inhibits murine anti-tumor immunity through its ability to generate Platelet-activating factor agonists. Carcinogenesis 2012; 33:1360-7.
16. Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK, Perkins SM, Speicher PJ, Tyler DS, Konger RL, Travers JB. Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 2014; 74(23):7069-78.
17. Hackler PC, Reuss S, Konger RL, Travers JB, Sahu RP*. Systemic Platelet-activating Factor Receptor Activation Augments Experimental Lung Tumor Growth and Metastasis. Cancer Growth Metastasis. 2014; 7:27-32.
18. Sahu RP*. Expression of the platelet-activating factor receptor enhances benzyl isothiocyanate-induced apoptosis in murine and human melanoma cells. Mol Med Rep. 2015;12(1):394-400.
19. Sahu RP*, Konger RL, Travers JB. Platelet-activating factor receptor agonists in tumor immunity. JSM Cell and Development. 2014; 2(1): 1008.
20. Sahu RP*, Ferracini M, Travers JB. Systemic chemotherapy is modulated by platelet-activating factor agonists. Mediators of Inflammation 2015. (In Press)